Biological
ALXN2220
ALXN2220 is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Active, not recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
active_not_recruiting267%
not_yet_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
not_yet_recruitingphase_2
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354
active_not_recruitingphase_3
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
active_not_recruitingphase_2
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
NCT07213583
Clinical Trials (3)
Showing 3 of 3 trials
NCT07608354Phase 2
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT06183931Phase 3
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT07213583Phase 2
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3